The purpose of this study is to measure the effect of multiple doses of orally administered povorcitinib on skin PK and to characterize plasma PK parameters of povorcitinib following multiple doses of orally administered povorcitinib.in healthy participants.

开始日期2024-08-12

申办/合作机构

Incyte Corp.

100 项与 Povorcitinib 相关的临床结果

登录后查看更多信息

100 项与 Povorcitinib 相关的转化医学

登录后查看更多信息

100 项与 Povorcitinib 相关的专利（医药）

登录后查看更多信息

项与 Povorcitinib 相关的文献（医药）

2024-06-01·JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Chronic Prurigo

Review

作者: Zeidler, Claudia ; Steinbrink, Kerstin ; Ständer, Sonja ; Müller, Svenja ; Thünemann, Julia

Summary:

Chronic prurigo (CPG) is a neuroinflammatory dermatosis characterized by prolonged pruritus lasting more than 6 weeks, pruriginous skin lesions, and repeated scratching.Patients with CPG suffer significantly from psychological distress and a marked impairment in their quality of life. The most common subtype of CPG is chronic nodular prurigo (CNPG, also called prurigo nodularis).In addition to the clinical features of CPG and the burden of disease, this CME article provides an overview of the significant advances in understanding the pathophysiology, including the associated therapeutic options for CPG. Dupilumab is the first approved therapy for moderate and severe CNPG to date from the European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). It also highlights other agents currently being studied in Phase II and Phase III clinical, randomized, placebo‐controlled trials. These include biologics such as nemolizumab (anti‐IL‐31‐RA‐mAb), vixarelimab/KPL‐716 (anti‐Oncostatin‐M receptor β‐mAb), and barzolvolimab/CDX‐0159 (anti‐KIT‐mAb), as well as Janus kinase inhibitors such as povorcitinib/INCB054707 and abrocitinib, and opioid modulators such as nalbuphine.

2024-05-17·BRITISH JOURNAL OF DERMATOLOGY

Prurigo nodularis: new insights into pathogenesis and novel therapeutics.

Review

作者: Ma, Emily ; Cornman, Hannah L ; Kwatra, Shawn G ; Liao, Viviane

Prurigo nodularis (PN) is an inflammatory skin condition characterized by intensely pruritic nodules on the skin. Patients with PN suffer from an intractable itch-scratch cycle leading to impaired sleep, psychosocial distress and a significant disruption in quality of life. The pathogenesis of PN is associated with immune and neural dysregulation, mediated by inflammatory cytokines [such as interleukin (IL)-4, -13, -17, -22 and -31] and neuropeptides (such as substance P and calcitonin gene-related peptide). There is a role for type 2 inflammation in PN in addition to T-helper (Th)17 and Th22-mediated inflammation. The neuroimmune feedback loop in PN involves neuropeptides released from nerve fibres that cause vasodilation and further recruitment of inflammatory cells. Inflammatory cells, particularly mast cells and eosinophils, degranulate and release neurotoxins, as well as nerve growth factor, which may contribute to the neuronal hyperplasia seen in the dermis of patients with PN and neural sensitization. Recent studies have also indicated underlying genetic susceptibility to PN in addition to environmental factors, the existence of various disease endotypes centred around degrees of type 2 inflammation or underlying myelopathy or spinal disc disease, and significant race and ethnicity-based differences, with African Americans having densely fibrotic skin lesions. Dupilumab became the first US Food and Drug Administration-approved therapeutic for PN, and there are several other agents currently in development. The anti-IL-31 receptor A inhibitor nemolizumab is in late-stage development with positive phase III data reported. In addition, the oral Janus kinase (JAK) 1 inhibitors, abrocitinib and povorcitinib, are in phase II trials while a topical JAK1/2 inhibitor, ruxolitinib, is in phase III studies.

2024-03-01·Journal of the American Academy of Dermatology

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Article

作者: Kimball, Alexa B ; Brown, Kurt ; Wang, Annie ; Porter, Martina L ; Kirby, Joslyn S ; Okun, Martin M ; Bechara, Falk G ; Alavi, Afsaneh ; Zouboulis, Christos C ; Bibeau, Kristen B ; Santos, Leandro L

BACKGROUND:

Janus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms.

OBJECTIVE:

To assess efficacy and safety of povorcitinib (selective oral Janus kinase 1 inhibitor) in HS.

METHODS:

This placebo-controlled phase 2 study randomized patients with HS 1:1:1:1 to receive povorcitinib 15, 45, or 75 mg or placebo for 16 weeks. Primary and key secondary end points were mean change from baseline in abscess and inflammatory nodule count and percentage of patients achieving HS Clinical Response at week 16.

RESULTS:

Of 209 patients randomized (15 mg, n = 52; 45 mg, n = 52; 75 mg, n = 53; placebo, n = 52), 83.3% completed the 16-week treatment. At week 16, povorcitinib significantly reduced abscess and inflammatory nodule count from baseline (least squares mean [SE] change: 15 mg, -5.2 [0.9], P = .0277; 45 mg, -6.9 [0.9], P = .0006; 75 mg, -6.3 [0.9], P = .0021) versus placebo (-2.5 [0.9]). More povorcitinib-treated patients achieved HS Clinical Response at week 16 (15 mg, 48.1%, P = .0445; 45 mg, 44.2%, P = .0998; 75 mg, 45.3%, P = .0829) versus placebo (28.8%). A total of 60.0% and 65.4% of povorcitinib- and placebo-treated patients had adverse events.

LIMITATIONS:

Baseline lesion counts were mildly imbalanced between groups.

CONCLUSION:

Povorcitinib demonstrated efficacy in HS, with no evidence of increased incidence of adverse events among doses.

项与 Povorcitinib 相关的新闻（医药）

2024-11-19

·BioPharmaDive

Incyte sinks on setback for drugs acquired in $750M buyout

Incyte has run into development hurdles with two drugs it acquired earlier this year, setting back the biotechnology companys plans to branch out from its top-selling medicine.Incyte said on Monday it will pause enrollment in a Phase 2 study testing a drug codenamed INCB000262 in a chronic form of hives, or urticaria. Incyte stopped the trial because of new results from a toxicology study in animals. The company didnt detail those findings, but said its shared them with the Food and Drug Administration and will work with the regulator to determine the programs next steps.Incyte has already completed enrollment in other proof-of-concept studies of INCB000262 in atopic dermatitis and inducible urticaria. Data from those trials will guide future development of the drug as well as back-up molecules, the company said.Incyte also revealed its scrapping another drug, INCB000547, due to Phase 2 results in a type of itching associated with liver disease that dont support further development.The announcement is a step backwards in Incytes long-running effort to solve its single-asset syndrome, a heavy reliance on the myelofibrosis drug Jakafi that still earns the bulk of its revenue. In the first nine months of the year, Jakafi accounted for nearly 80% of the companys roughly $2.6 billion in net product sales. But the drug is facing increasing competition and could lose patent protection later this decade.Incyte has been attempting to lessen its dependence on Jakafi by branching out into dermatology, immunology and some rare blood cancers. While its had some success with in-house research bringing to market a cream form of Jakafi it sells for a pair of skin conditions dealmaking has become a focus over the last few years. A partnership with Syndax Pharmaceuticals yielded a drug for graft-versus-host disease it now sells as Niktimvo. The lymphoma drug Monjuvi was acquired from biotech MorphoSys. The company has also acquired a pair of startups, buying the dermatology focused biotech Villaris in 2022 and striking a deal for privately held immune drug developer Escient Pharmaceuticals in April.The Escient buyout was the largest of those bets a $750 million deal that gave the company what Wall Street analysts viewed as a high-profile drug candidate. INCB000262 is a potential oral treatment for urticaria, a common condition thats a target of several drugmakers. Its one of at least two programs in development that blocks a protein called MRGPRX2 thats expressed on the mast cells thought to drive the disease. The drug has the potential to be transformative, if successful, wrote RBC Capital Markets analyst Brian Abrahams on Monday.Yet, after speaking with Incyte executives, Abrahams noted there is still uncertainty on what the next steps are for INCB000262. Should development continue, results from all three proof-of-concept studies could come in early 2025. If not, Incyte wont disclose data, though backup drugs could enter human testing relatively shortly thereafter, he wrote.The study pause puts a significant $1.8 billion [revenue] opportunity at risk, and risks impairing the growing enthusiasm on the rest of the pipeline, Abrahams added.Investors will now pay even closer attention to a Phase 3 readout next year for a drug, povorcitinib, in the autoimmune condition hidradenitis suppurativa, wrote William Blair analyst Matt Phipps.Incyte shares fell more than 10% in early trading Tuesday. '

并购临床2期临床3期

2024-10-22

·PRNewswire

JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the Domain

JAK inhibitors are a class of medications that work by blocking Janus kinases (JAKs), enzymes that are involved in the signaling pathways of various cytokines and growth factors. JAK inhibitors offer a more targeted approach to treating immune-mediated diseases compared to traditional therapies like corticosteroids or conventional immunosuppressants; this specificity reduces side effects and increases efficacy and is a major driver for the demand for JAK inhibitors. LAS VEGAS, Oct. 22, 2024 /PRNewswire/ -- DelveInsight's ' JAK Inhibitors Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline JAK inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the JAK inhibitors pipeline domain. Key Takeaways from the JAK Inhibitors Pipeline Report DelveInsight's JAK inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline JAK inhibitors. Key JAK inhibitors companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma, Esker Therapeutics, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical and others are evaluating new JAK Inhibitors drugs to improve the treatment landscape. Promising pipeline JAK inhibitors such as Povorcitinib, CPL409116, ATI-2138, SDC 1802, AZD 4604, INCB-160058, Research programme: JAK2 inhibitors, Ritlecitinib, Momelotinib, DZD4205, ATI 2138, CPL 409116, Itacitinib, Ivarmacitinib, ESK 001, Repotrectinib, Rovadicitinib, and others are under different phases of JAK inhibitors clinical trials. In October 2024, Pelabresib in combination with ruxolitinib showed benefit in treating patients with JAK Inhibitor-Naïve Myelofibrosis significantly reduced splenomegaly, and improved anemia that has not been previously treated with Janus kinase inhibitors (JAKis). In September 2024, Eli Lilly and Company and EVA Pharma announced that the companies have agreed to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. In May 2024, Ajax Therapeutics, Inc., announced that it had received clearance for its Investigational New Drug application from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study of AJ1–11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis. In February 2024, Novartis announced that it intends to acquire MorphoSys. The acquisition, which was unanimously approved by the boards of both Novartis and MorphoSys, is expected to close in the first half of 2024, subject to customary closing conditions. In January 2024, NS Pharma received orphan drug designation (ODD) from the European Commission (EC) for NS-229, which is being developed to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease. In December 2023, Sun Pharmaceuticals Inc. announced that it has entered a licensing agreement with Aclaris Therapeutics Inc., the company announced in a regulatory filing. Under the agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). Request a sample and discover the recent advances in JAK inhibitors drugs @ JAK Inhibitors Pipeline Report The JAK inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage JAK inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the JAK inhibitors clinical trial landscape. JAK Inhibitors Overview Janus kinase (JAK) inhibitors are a class of medications designed to interfere with the activity of the Janus kinase family of enzymes, which play a crucial role in the signaling pathways of immune responses. These enzymes are key mediators in transmitting signals from cytokines and growth factors, which regulate blood cell production and immune system function. By blocking these signals, JAK inhibitors help to control the overactive immune response seen in several inflammatory and autoimmune diseases. They have shown significant efficacy in treating conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, among others. The most common JAK inhibitors include tofacitinib, baricitinib, and upadacitinib, which are administered orally. Beyond their role in autoimmune diseases, JAK inhibitors are also being explored for use in treating certain cancers and myeloproliferative disorders, where abnormal JAK signaling contributes to uncontrolled cell growth. In diseases like myelofibrosis and polycythemia vera, JAK inhibitors can help reduce symptoms and improve quality of life. However, there are potential side effects associated with their use, including increased susceptibility to infections, blood clots, and cardiovascular risks, given their impact on the immune system. As research continues, the therapeutic potential of JAK inhibitors is expanding, offering new hope for patients with difficult-to-treat conditions. Find out more about JAK inhibitors drugs @ JAK Inhibitors Analysis A snapshot of the Pipeline JAK Inhibitors Drugs mentioned in the report: Learn more about the emerging JAK inhibitors @ JAK Inhibitors Clinical Trials JAK Inhibitors Therapeutics Assessment The JAK inhibitors pipeline report proffers an integral view of the emerging JAK inhibitors segmented by stage, product type, molecule type, and route of administration. Scope of the JAK Inhibitors Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Key JAK Inhibitors Companies: Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma, Esker Therapeutics, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical, and others. Key JAK Inhibitors Pipeline Therapies: Povorcitinib, CPL409116, ATI-2138, SDC 1802, AZD 4604, INCB-160058, Research programme: JAK2 inhibitors, Ritlecitinib, Momelotinib, DZD4205, ATI 2138, CPL 409116, Itacitinib, Ivarmacitinib, ESK 001, Repotrectinib, Rovadicitinib, and others. Dive deep into rich insights for new JAK inhibitors, visit @ JAK Inhibitors Drugs Table of Contents For further information on the JAK inhibitors pipeline therapeutics, reach out @ JAK Inhibitors Therapeutics Related Reports JAK Inhibitors Market JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Eli Lilly and Company, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Incyte Corporation, Kartos Therapeutics, Inc., Dompé Farmaceutici S.p.A, Sanofi, Kiniksa Pharmaceuticals, Ltd., Celgene, Abivax S.A., Telios Pharma, Inc., AstraZeneca, Karyopharm Therapeutics Inc, TWi Biotechnology, Inc., Geron Corporation, Ajax Therapeutics, Inc., among others. JAK Inhibitors Competitive Landscape JAK Inhibitors Competitive Landscape – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others. KRAS Inhibitors Market KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio , among others. PD/L-1 Inhibitors Market PD/L-1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD/L-1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期引进/卖出并购孤儿药

2024-09-25

·incyte

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 25, 2024-- Incyte (Nasdaq:INCY) today announced that key data from across its dermatology portfolio, including multiple late-breaking abstracts, will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2024 held September 25-28 in Amsterdam. “We’re excited to present five late-breaking oral presentations at this year’s congress, featuring data that could further expand treatment options for those living with immune-mediated dermatologic conditions, including vitiligo, atopic dermatitis, hidradenitis suppurativa and prurigo nodularis,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “The data highlight our ongoing efforts to evaluate the efficacy and safety of ruxolitinib cream in new patient populations, as well as deepen our understanding of povorcitinib in patients impacted by debilitating immune-mediated dermatologic conditions.” Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Impact of Treatment Duration on Response Durability: A Post Hoc Analysis of the TRuE-V Long-Term Extension Study of Ruxolitinib Cream in Vitiligo Abstract #8077. Session: D2T01.3: Late breaking news. Presentation Time: 9:15 – 9:30 a.m. ET (3:15 – 3:30 p.m. CET), September 26, 2024 Atopic Dermatitis 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study Abstract #8082. Session: D2T01.4: Late breaking news. Presentation Time: 10:00 – 10:15 a.m. ET (4:00 – 4:15 p.m. CET), September 26, 2024 Hidradenitis Suppurativa Ruxolitinib Cream for Mild-to-Moderate Hidradenitis Suppurativa: 32-Week Data From a Randomized Phase 2 Study Abstract #8071. Session: D2T01.3: Late breaking news. Presentation Time: 9:00 – 9:15 p.m. ET (3:00 – 3:15 p.m. CET), September 26, 2024 Prurigo Nodularis Efficacy and Safety of Oral Povorcitinib in Patients With Prurigo Nodularis: 40-Week Results From a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Abstract #8081. Session: D2T01.3: Late breaking news. Presentation Time: 9:30 – 9:45 a.m. ET (3:30 – 3:45 p.m. CET), September 26, 2024 Lichen Planus Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: Results From a Phase 2, Randomized, Vehicle-Controlled Study Abstract #7974. Session: D3T01.4: Late breaking news. Presentation Time: 10:30 – 10:45 a.m. ET (4:30 – 4:45 p.m. CET), September 27, 2024 ePosters Vitiligo Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo Through 2 Years in the TRuE-V Studies Poster #P2983. Characterizing Maintenance of Repigmentation in a Post Hoc Analysis of the TRuE-V Long-Term Extension Study of Ruxolitinib Cream in Vitiligo Poster #P2984. Effect of Povorcitinib on Achievement of VASI50 by Body Region in Patients With Extensive Nonsegmental Vitiligo: Post Hoc Analysis of a 52-Week Phase 2 Study Poster #P3016. Effect of Povorcitinib on Achievement of VESplus50 by Body Region in Patients With Extensive Nonsegmental Vitiligo: Post Hoc Analysis of a 52-Week Phase 2 Study Poster #P3017. Full session details and data presentation listings, please see the EADV 2024 Congress online program here: https://eadvapps.m-anage.com/eadvcongress2024/en-GB/pag/ About Opzelura® (ruxolitinib) Cream 1.5% Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended. In Europe, Opzelura (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States and Europe as Opzelura. Opzelura and the Opzelura logo are registered trademarks of Incyte. About Povorcitinib (INCB54707) Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for vitiligo, hidradenitis suppurativa (HS) and prurigo nodularis. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, the promise presented by that pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions and Incyte’s goal of improving the lives of patients, contain predictions, estimates, and other forward-looking statements. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended June 30, 2024. We disclaim any intent or obligation to update these forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20240925048109/en/ Media media@incyte.com Investors ir@incyte.com Source: Incyte

临床3期临床结果临床2期上市批准

100 项与 Povorcitinib 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结节性痒疹	临床3期	美国	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	日本	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	阿根廷	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	澳大利亚	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	奥地利	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	比利时	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	保加利亚	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	加拿大	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	智利	Incyte Corp.	2024-10-10
结节性痒疹	临床3期	捷克	Incyte Corp.	2024-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05061693 (CTgov)	临床2期	结节性痒疹	146	placebo (Placebo)	齋構鑰餘壓廠鑰壓憲觸(獵觸簾獵廠獵範簾蓋積) = 構糧獵夢餘鹽遞鹽遞襯膚襯蓋網顧衊壓繭夢願 (簾艱繭夢鹹繭糧衊築願, 遞積構齋齋艱淵繭鹹遞 ~ 鑰顧觸餘鏇製襯鏇獵鑰) 更多	-	2024-08-27
				Povorcitinib (Povorcitinib 15 mg)	齋構鑰餘壓廠鑰壓憲觸(獵觸簾獵廠獵範簾蓋積) = 襯積製鹽憲廠獵製糧築膚襯蓋網顧衊壓繭夢願 (簾艱繭夢鹹繭糧衊築願, 淵膚構製願蓋壓鏇鬱鹹 ~ 鏇膚淵構觸鏇構製鬱鏇) 更多
NCT05061693 (Corporate Publications) 人工标引	临床2期	结节性痒疹	146	Povorcitinib 15 mg	遞積鏇願築鏇製願艱壓(製鏇鹽糧廠蓋築糧齋糧) = 鬱鹹簾鏇簾衊窪蓋齋鏇齋蓋蓋壓廠獵顧構憲壓 (糧鬱鑰夢積淵鹹廠艱遞 ) 达到更多	积极	2024-03-10
				Povorcitinib 45 mg	遞積鏇願築鏇製願艱壓(製鏇鹽糧廠蓋築糧齋糧) = 觸蓋淵淵壓鑰遞餘顧顧齋蓋蓋壓廠獵顧構憲壓 (糧鬱鑰夢積淵鹹廠艱遞 ) 达到更多
NCT04818346 (AAD2024) 人工标引	临床2期	-	171	Povorcitinib (age≤40 years)	淵蓋鬱築築廠獵壓糧鏇(壓範築選糧糧選願艱構) = 淵膚觸壓繭選齋遞觸壓餘餘齋網製構壓淵積廠 (構築構窪簾醖壓夢積廠 )	积极	2024-03-10
				Povorcitinib (age>40 years)	淵蓋鬱築築廠獵壓糧鏇(壓範築選糧糧選願艱構) = 簾範鹹鹹繭醖膚憲網鹹餘餘齋網製構壓淵積廠 (構築構窪簾醖壓夢積廠 )
NCT04818346 (Corporate Publications) 人工标引	临床2期	非节段型白癜风	171	povorcitinib15-to-75 mg	餘淵製衊襯築構蓋鬱鏇(糧醖廠構夢繭淵餘網願) = 鹹築齋顧鹽網齋夢淵顧壓顧獵壓簾願壓繭構艱 (憲蓋選夢鬱淵顧襯繭鑰 ) 更多	积极	2023-10-11
				povorcitinib45 mg	餘淵製衊襯築構蓋鬱鏇(糧醖廠構夢繭淵餘網願) = 壓襯鏇積遞蓋糧選網製壓顧獵壓簾願壓繭構艱 (憲蓋選夢鬱淵顧襯繭鑰 ) 更多
NCT04818346 (phase 2b, EADV2023)	临床2期	白癜风 Fitzpatrick skin types I - III	171	Povorcitinib 15 mg	鹽糧範艱鏇鑰鹽糧糧繭(製艱醖窪構餘糧艱鹽築) = 鹽鹹衊艱鑰鹽窪選繭顧襯衊製襯窪選鏇衊鑰壓 (糧願膚糧鹽繭獵鹹鬱觸 )	积极	2023-10-11
				Povorcitinib 45 mg	鹽糧範艱鏇鑰鹽糧糧繭(製艱醖窪構餘糧艱鹽築) = 網網糧憲艱觸獵鏇積窪襯衊製襯窪選鏇衊鑰壓 (糧願膚糧鹽繭獵鹹鬱觸 )
EADV2023	临床2期	-	209	Povorcitinib 15 mg	築遞膚鏇網鏇廠範衊鏇(獵鹹鹽膚願鹹鑰獵淵積) = 選壓憲構壓鬱網夢獵獵簾範顧憲網網願糧顧壓 (鑰壓窪壓鹽衊夢襯願願 )	-	2023-10-11
				Povorcitinib 45 mg	築遞膚鏇網鏇廠範衊鏇(獵鹹鹽膚願鹹鑰獵淵積) = 選夢憲餘膚顧夢糧窪觸簾範顧憲網網願糧顧壓 (鑰壓窪壓鹽衊夢襯願願 )
NCT04476043 (phase 2 study, EHSF2023)	临床2期	化脓性汗腺炎	174	Povorcitinib 15 mg	網鏇繭窪構齋窪簾襯願(壓鏇蓋積積廠鹽夢簾壓) = 11.5% 餘觸範繭願窪鏇構憲構 (鏇齋製願築艱壓淵糧糧 ) 更多	积极	2023-09-27
				Povorcitinib 45 mg
NCT04818346 (phase 2b, CTgov)	临床2期	非节段型白癜风	171	placebo+povorcitinib (Placebo)	鹹鏇獵廠糧簾獵築繭鏇(鹹製齋鬱鑰積鬱糧糧窪) = 選遞膚鹹網糧鹽醖鏇鹹憲鹽醖範鹹鹹繭構觸淵 (鹹鬱糧窪膚餘憲壓簾顧, 觸窪遞襯網鑰簾積鹹鹽 ~ 積壓觸鏇築齋餘襯憲繭) 更多	-	2023-07-05
				Povorcitinib (Povorcitinib 15 mg)	鹹鏇獵廠糧簾獵築繭鏇(鹹製齋鬱鑰積鬱糧糧窪) = 積蓋餘餘願鑰鏇構範衊憲鹽醖範鹹鹹繭構觸淵 (鹹鬱糧窪膚餘憲壓簾顧, 顧齋膚願齋衊構壓衊壓 ~ 淵廠簾艱憲膚鬱壓觸夢) 更多
NCT04476043 (phase 2 dose-ranging study \| phase 2 study, CTgov)	临床2期	化脓性汗腺炎	209	INCB054707 (INCB054707 15 mg)	繭餘選鏇製鏇餘糧範淵(窪廠齋網壓憲鏇糧簾艱) = 齋網鹹襯觸範觸鹽製顧鹽廠膚淵網顧襯醖鏇鬱 (鏇襯襯遞壓鏇鏇壓襯顧, 獵夢網蓋憲鑰醖淵夢顧 ~ 餘選遞廠艱獵製壓獵製) 更多	-	2023-01-26
				INCB054707 (INCB054707 45 mg)	繭餘選鏇製鏇餘糧範淵(窪廠齋網壓憲鏇糧簾艱) = 餘遞遞夢構築願糧窪範鹽廠膚淵網顧襯醖鏇鬱 (鏇襯襯遞壓鏇鏇壓襯顧, 範壓鹹鏇壓鬱遞餘餘製 ~ 淵鬱壓夢淵顧繭窪選積) 更多
NCT04476043 (phase 2 dose-ranging study, EADV2022)	临床2期	化脓性汗腺炎	209	INCB054707 15 mg	構憲窪鏇觸範憲繭夢鏇(膚構壓顧夢繭憲襯鹹簾) = 鑰鹽觸網繭鏇醖獵壓鏇製壓淵襯顧構鏇醖廠獵 (鹽窪蓋鑰蓋觸夢遞窪範 ) 更多	积极	2022-09-07
				INCB054707 45 mg	構憲窪鏇觸範憲繭夢鏇(膚構壓顧夢繭憲襯鹹簾) = 構築鑰積網繭鹽範獵餘製壓淵襯顧構鏇醖廠獵 (鹽窪蓋鑰蓋觸夢遞窪範 ) 更多